发明名称 |
COMBINATION THERAPIES OF EGFR INHIBITORS |
摘要 |
Combination therapies are disclosed, comprising the selective mutated EGFR inhibitor EGF816 and an immunomodulator chosen from one or more of an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule. An example of such an inhibitor of an immune checkpoint molecule is the anti-PD-1 monoclonal antibody Nivolumab. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders. |
申请公布号 |
WO2016040882(A1) |
申请公布日期 |
2016.03.17 |
申请号 |
WO2015US49813 |
申请日期 |
2015.09.11 |
申请人 |
NOVARTIS AG;LEBWOHL, DAVID;PETERS, MALTE |
发明人 |
LEBWOHL, DAVID;PETERS, MALTE |
分类号 |
A61K39/395;A61K31/506;A61K31/55;A61K39/00;A61P35/00;C07K16/28 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|